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Abstract
Background: There are currently 7 known serotypes of botulinum neurotoxin (BoNT) classified upon non-cross reactivity of
neutralizing immunoglobulins. Non-neutralizing immunoglobulins, however, can exhibit cross-reactivities between 2 or
more serotypes, particularly mosaic forms, which can hamper the development of highly specific immunoassays, especially
if based on polyclonal antisera. Here we employ facile recombinant antibody technology to subtractively select ligands to
each of the 7 BoNT serotypes, resulting in populations with very high specificity for their intended serotype.
Methods and Findings: A single llama was immunized with a cocktail of 7 BoNT toxoids to generate a phage display library
of single domain antibodies (sdAb, VHH or nanobodies) which were selected on live toxins. Resulting sdAb were capable of
detecting both toxin and toxin complex with the best combinations able to detect 100s-10s of pg per 50 mL sample in a
liquid bead array. The most sensitive sdAb were combined in a heptaplex assay to identify each of the BoNT serotypes in
buffer and milk and to a lesser extent in carrot juice, orange juice and cola. Several anti-A(1) sdAb recognized A2 complex,
showing that subtype cross-reactivity within a serotype was evident. Many of our sdAb could act as both captor and tracer
for several toxin and toxin complexes suggesting sdAb can be used as architectural probes to indicate BoNT
oligomerisation. Six of 14 anti-A clones exhibited inhibition of SNAP-25 cleavage in the neuro-2A assay indicating some
sdAb had toxin neutralizing capabilities. Many sdAb were also shown to be refoldable after exposure to high temperatures
in contrast to polyclonal antisera, as monitored by circular dichroism.
Conclusions: Our panel of molecularly flexible antibodies should not only serve as a good starting point for ruggedizing
assays and inhibitors, but enable the intricate architectures of BoNT toxins and complexes to be probed more extensively.
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Introduction
Botulinum neurotoxins (BoNT) are still the most poisonous
naturally occurring substances known [1], with extrapolations
from non-human primate studies indicating that lethal doses for
humans would be 1 mg/kg, 10 ng/kg or 1 pg/kg for oral,
inhalation and injection routes respectively [2,3,4]. For perspec-
tive, it has been estimated that BoNT are 100 billion times more
toxic than cyanide [5]. The extreme potency, widespread
distribution in soils of producing strains, and relative ease of
production has meant that BoNT are the only toxins in the highest
risk group i.e., CDC category A, of biological agents thought to
pose a potential threat alongside Marburgvirus and Bacillus anthracis
[6,7]. Indeed, it has been predicted that contamination of
centralized milk supplies could result in hundreds of thousands
of cases in the absence of suitable detection methods [8] and it has
been speculated that, ‘‘it is likely only a matter of time until
botulism is intentionally caused…’’ [9]. Since intoxication can
result in a paralysis so severe it can require mechanical ventilation
for weeks to months, it would be facile to overwhelm health
authorities and cause mass casualties via BoNT mis-use [9,10].
Specific species of the spore forming anaerobe Clostridium
produce BoNT as 150 kDa proteins with one or more neurotoxin
accessory proteins (NAPs) to form toxin complexes or progenitors
of varying sizes approximately 300, 500, and 900 kDa known as
M, L and LL. The NAPs shield the toxin from the harsh protease
rich environments of the stomach and intestine, elevating the
potency of the ingestion route several hundred fold over toxin and
may also play a role in uptake across the intestinal epithelium. The
toxins themselves consist of an N-terminal translocation domain
(Hn or HCT) and C-terminal receptor binding domain (Hc or
HCR) comprising a 100 kDa heavy chain (HC) fragment, which is
disulfide linked to a 50 kDa proteolytic light chain domain (LC or
Lc). The Hc targets receptors on pre-synaptic membranes at
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Hn is subsequently triggered by low pH to translocate the Lc into
the cytosol. Lc cleaves specific proteins involved in acetylcholine
release to inhibit nerve transmission and cause muscle relaxation
(for recent review see [11]).
There are 7 serotypes of BoNT (A, B, C, D, E, F and G) based
upon non-cross-reactive neutralizing antisera specific to the
150 kDa toxin component. While A, B, E, and F have been
definitively linked to human botulism, G has been implicated in 7
cases of sudden unexpected deaths [12,13], and C, D are typically
associated with farming/wildlife outbreaks. Importantly, all 7
serotypes have been shown to be highly lethal in non-human
primate models [3]. Neutralizing sera are not necessarily
absolutely specific since cross-neutralization can occur between
E and A [14], B, F [15]. A non-protective antibody cross-reactive
with B, C, D and E has been isolated [16] and polyclonal
antibodies raised to fragments of A have been shown to cross react
with heterologous holotoxins [17]. Furthermore, serotypes D and
C have high Lc and Hn homologies, which can confer cross-
reactivity to antibodies [18,19] and some C/D and D/C toxins are
‘‘mosaics’’ with low homology to either parent in the Hc domain
[20]. Several serotypes have subtypes (currently A=5, C=2,
D=2, E=3 and F=4) that can show reduced reactivity towards
antibodies to the major subtype [21,22,23]. Indeed, sequence
divergence of the BoNT is substantial considering they share many
similarities in a complex series of functions [24]. For example,
each serotype has a unique protease cleavage site specificity within
the SNARE complex, though often in shared targets with A and E
recognizing SNAP-25, B, D, F and G recognizing VAMP and C
recognizing both SNAP-25 and syntaxin. The cleavage specificities
of various subtypes are under study with remarkable differences in
cleavage rates among recombinant Lc of A1-A4 already being
observed using synthetic SNAPtide substrate [25].
The NAPs tend to be less conserved across serotypes, though
homologies have been identified from recent genomic studies
[26,27] and cross-reactivities have been noted from immunological
studies [28,29,30]. Within those subtypes so far studied, NAPS can
also vary, with prominent components such as HA33 of subtype A1
being present in A4 but not A2 or A3 for example [27]. Thus, the
addition of NAPs to toxin varies according to serotype and
potentially subtype: A exists in M, L and LL forms; B/C/D/E in
L and M forms; F in M form; and G inL form.C. botulinum normally
produces one of A, B, C, D, E or F and C. argentinense produces G. C.
butyricum and C. baratii also produce E and F, respectively, yet the E
has been shown to be partially immunologically distinct from the
botulinum E counterpart [31] and the F is even more divergent [32]
and expectedtobesero-distinguishable.SomeB and allEstrainsare
non-proteolytic and so the toxin is a single chain molecule that may
have different surface topography to the component chains once
nicked and activated as shown for serotype E [33]. To complicate
matters more, bivalent strains of C. botulinum exist, which can
produce two different serotypes (Ab, Af, Ba, or Bf) where the capital
letter indicates the prominent serotype [15]. Finally, the NAPs have
been shown to occlude the recognition of toxin by particular
antibodies [34], though exposure to high pH can reduce this steric
hindrance [35,36]. As can be seen, immunoassay development for
BoNT and their complexes is extremely challenging!
We are interested in developing disruptive antibody technolo-
gies to probe and counter high consequence targets, and one
aspect of this employs llama single domain antibodies (sdAb or
nanobodies) to generate rugged ligands [30,37,38]. SdAb are
derived by cloning the variable domains of the heavy chain only
antibody of Camelids or IgNAR of sharks and expressing them
recombinantly (see [39,40,41] for reviews). SdAb are highly
soluble, well expressed, and have been shown to refold after
thermal or chemical denaturation unlike conventional multi-
domain immunoglobulins or their recombinant derivatives
[42,43,44,45]. At approximately 1/10
th the size of an IgG, their
compact architecture is proving advantageous in accessing cryptic
epitopes normally out of bounds to standard immunoglobulins
[46,47] potentially offering new routes of neutralization. SdAb also
appear highly capable of crystallizing and co-crystallizing with
their target antigens to enable high resolution structures of even
fickle targets to be obtained [48,49].
With all of these advantages in hand, we reasoned that sdAb
would make ideal candidates to begin probing the complex
antigenic make-up of the BoNT molecules and offer potentially
novel inhibitory routes. Therefore, we chose to generate sdAb to
all 7 BoNT serotypes and examine their specificities and
sensitivities on both toxins and toxin complexes. We also examined
the in vitro neutralizing ability and the molecular flexibility of some
of the sdAb obtained.
Results and Discussion
Generating Anti-BoNT sdAb
We immunized a single llama with a cocktail of all 7 serotypes of
the toxins as toxoids and observed seroconversion against toxoids,
toxins and toxin complexes by ELISA (Figure 1). We used 6
immunizations yet did not see appreciable increase in seroconver-
sion between doses 4 and 6, suggesting the response had plateaued
(data not shown). After the final immunization, we cloned the
variable heavy chain repertoire into a phage display vector using
variable heavy domain framework 1 and 4 specific primers to
capture VHH and VH genes since the latter have been shown to
produce sdAb with favorable biophysical characteristics too [50].
The library was approximately 1e+9 clones with 24/24 unique
clones having inserts at a ratio of almost 2 VH: 1VHH as judged by
examining the amino acid composition of framework 2 [51].
The library was mined for BoNT binders by selections on
biotinylated toxins in the presence of excess non-biotinylated
decoy toxins, resulting in the isolation of polyclonal phage mostly
specific for the serotype upon which they were selected except for
those selected on C (C1) and D (Figure 2). Serotypes C and D
share regions of homology, particularly in the Hn domain [20],
implying that some sdAb selected on D or C could be cross-
reactive. Furthermore, the D serotype supplied by Metabiologics is
actually a D/C mosaic, and while it shares high Hn homology and
partial Lc homology, it differs from both D and C parental
serotypes in its Hc [20].
The polyclonal phage populations were deconvoluted by
monoclonal phage ELISA on the serotype of toxin upon which
they were selected and positive clones sequenced to reveal several
unique predicted amino acid sequences for each serotype A(18),
B(21), C(26), D(36), E(8), F(10) and G(27) (Figure S1). It is
noteworthy that only 10 of 146 unique sequences were VH (A14,
A15, B21, D4, D5, D12, D13, D19, D20 and G24) suggesting that
there may actually be a counter-selection against these domains
perhaps due to the lack of affinity contributions by VL. However,
the dominance of VH over VHH has recently been shown for
cancer marker antigens [52], indicating that the target require-
ment for VL contributions and/or other factors are at play.
Despite the cross-reactivity between C and D, we could not
identify any clones that were common to both populations.
Characterization of Anti-BoNT sdAb Serotype Specificity
We managed to subclone, express and purify over 100 different
sdAb genes A(18), B(19), C(22), D(28), E(8), F(9) and G(22) for
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suspension microarrays (Luminex). Each antibody was coupled to
a unique bead region so that the mix of captors could be analyzed
against each biotinylated tracer individually for specificity to be
gauged and a first indication of sensitivity to be noted. To choose
appropriate clones, we used a concentration of 1e+5 pg BoNT per
well, which did not saturate our ligands and so resulted in
sensitivity discrimination. First, we chose an upper limit of
approximately 500 median fluorescent intensities (MFI) from this
data to rule out relatively insensitive combinations that would not
have the dynamic range we sought (ideally several thousand MFI).
Second, we calculated the percentage cross-reactivity of each pair
on mixes of decoy toxins and toxin complexes (Tables S1).
Almost all sdAb were capable of highly specific recognition of
the serotype upon which they were selected apart from some of the
C and most of the D populations, presumably owing to the
homologies previously discussed. Typically, for each pair of sdAb
captor and tracer, the mean percentage cross-reactivity on a mix
of non-cognate or decoy serotypes was below 0.1%. High
resolution of target serotype indicates that, apart from when
mosaic toxins are encountered, subtractive panning on live
holotoxins is capable of delivering ligands with the desired
specificity. The anti-C clones that did have high reactivities on
non-cognate mixes were further examined to confirm that it was D
(D/C mosaic) reactivity rather than broader cross-reactivity (data
not shown). We therefore did not pursue anti-C clones that
showed high cross-reactivities further. Since the E proteins we
used were based upon non-activated forms we expect our clones to
be able to detect naturally occurring forms and further studies will
be needed to determine if they are capable of recognizing the
dichain molecules.
All sdAb were capable of binding both toxin and toxin complex
suggesting that 1) either the sdAb targeted epitopes on the toxin
not shielded by the complex of NAP proteins as seen with some
Figure 2. Capturing the llama anti-BoNT repertoire by phage display. Polyclonal phage ELISA of round 2 selected phage populations
analyzed on each a) toxin or b) toxin complex indicates the potential degree of specificity for the serotype of toxin upon which the population was
selected.
doi:10.1371/journal.pone.0008818.g002
Figure 1. Seroconversion of Snoop the llama after being immunized with the 7 serotypes of BoNT toxoids. Antibody capture from
serum after the 6
th immunization was monitored on the seven serotypes of a) toxoid, b) toxin and c) toxin complexes versus a control antigen, bovine
serum albumin (BSA).
doi:10.1371/journal.pone.0008818.g001
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not shielding the toxin effectively. We found it odd that none of our
sdAb to any serotype appeared to be occluded by the complex
proteins and it would be tempting to speculate that the small size
of the sdAb may enable them to penetrate the NAP shield and
target the toxin beneath. However, it is important to note that our
PBSTB assay buffer is pH 7.3, which may encourage the
dissociation of the complexes which is favored by alkaline
pH 7.5–8 [35,36,53,54]. However, as noted below, the range of
sdAb able to act as both tracer and captor varied between toxin
and complex, indicating that toxin epitopes were not identically
presented, inferring that complex dissociation was not occurring or
was incomplete.
Many sdAb could perform as both captor and tracer, thereby
hinting at the oligomeric potential of some toxins and their
complexes. It has been found previously that at pH 7.0 toxin A
can be detected as a dimer, trimer and higher species, B as a
dimer, and E as a dimer and monomer [55]. We noticed sdAb
clones B2, B3, B5, B7, B17 and B18 were capable of detecting
toxin when used alone and also capable of detecting complex
alone, as were B4, B6, B10, B13, B14 and B20. Only C6 could
detect toxin alone, yet C3, C4, C6, C7, C8, C22 and C25 were
able to detect complex. D22, E8, F5 and F9 were also single-
handedly able to detect their respective toxins and toxin
complexes. Of the anti-G clones, only G11, when used alone,
was able to detect toxin, while G2, G3, G4, G11 and G18 were all
able to detect complex. Therefore, it is possible that B, C, D, E, F,
G toxin complexes, and perhaps C, F and G toxins also form
dimers or higher structures, though cross-linking and other
biophysical analyses will naturally be needed to confirm these
suspicions.
The pairs with the lowest cross-reactivity and therefore the
highest specificity are presented in Table 1 with the values
obtained using rabbit polyclonal sera as controls to demonstrate
improved specificities of sdAb. Our sdAb are between 775 fold (B
complex) and 48 fold (C toxin) less cross-reactive than the
corresponding rabbit polyclonal sera.
Characterization of Anti-BoNT sdAb Sensitivity
The best pair of sdAb against each serotype was then employed
in a titration of cognate toxin and toxin complex to determine the
lower limits of detection (Figure 3). Our threshold was set at the
MFI value obtained by multiplying by ten, the MFI yielded on
1e+5 pg mix of non-target serotype. Since there can be batch to
batch variation of toxin preparations and a standardized mouse
bioassay can be used to normalize active toxin concentrations
between them, we also calculated the lower LOD in MLD50 based
upon activity data kindly provided by Metabiologics. We therefore
estimate our lower LOD per 50 mL sample to be approximately
30 pg (0.81 MLD50) of A toxin, 100 pg (3.5 MLD50) of A complex,
Table 1. Comparison of cross-reactivities of the chosen sdAb pairs specific for each serotype and rabbit polyclonal antibodies
when challenged with 1e+5 pg of toxins or toxin complexes.
Antigen Captor Tracer Cognate mMFI
1 Non-cognate mMFI
2 % Cross-reactivity
A toxin A18 A17 7349677 2.2560.25 0.03
B toxin B4 B2 18716247 1.2560.75 0.07
C toxin C1 C24 7009661 8.062.0 0.11
D toxin D22 D16 1393648 32.2560.25 2.32
E toxin E7 E4 3052658 2.7560.75 0.09
F toxin F9 F5 7032677 4.560.5 0.06
G toxin G20 G3 50086197 1.560.5 0.05
A toxin A Rab A Rab 910640 11168.5 12.1
B toxin B Rab B Rab 2226634 12564.75 5.6
C toxin C Rab C Rab 1453671 77625 . 3
E toxin E Rab E Rab 388641 4761.75 12.2
F toxin F Rab F Rab 415627 4262 10.1
A complex A18 A17 40916102 2.060 0.05
B complex B4 B2 113906130 2.060 0.02
C complex C1 C24 37666358 3.2560.75 0.09
D complex D22 D16 1343678 4.0620 . 3
E complex E7 E4 23116126 3.560.5 0.15
F complex F9 F5 59406113 7.560.5 0.13
G complex G20 G3 53746357 2.060 0.04
A complex A Rab A Rab 16906205 68684 . 0
B complex B Rab B Rab 2655657 411623.5 15.5
C complex C Rab C Rab 808640 7768.5 9.5
E complex E Rab E Rab 470635 5361.25 11.2
F complex F Rab F Rab 247612 3665.5 14.4
1Cognate refers to the serotype on which the sdAb were selected upon or raised against (for the rabbit sera).
2Non-cognate refers to a mix of all other serotypes at 1e+5 pg each.
1,2mMFI, mean median fluorescent intensity.
doi:10.1371/journal.pone.0008818.t001
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complex, 300 pg (7.2 MLD50) of C toxin, 600 pg (4.2 MLD50)o f
C complex, 500 pg (45 MLD50) of D toxin, 60 pg (1.74 MLD50)o f
D complex, 80 pg (4.8 MLD50) of E toxin, 300 pg (9 MLD50)o fE
complex, 30 pg (0.6 MLD50) of F toxin, 200 pg (0.64 MLD50)o fF
complex, 100 pg (1.4 MLD50) of G toxin and 70 pg (0.27 MLD50)
of G complex. A heptaplex assay was established in buffer, milk,
orange, carrot juice and cola (Figure 4) revealing that the panel
could detect and discriminate all serotypes when present at
1e+4 pg/well in buffer and milk, but to a lesser extent in the other
matrices. We relied on microfiltration for our assay and had to
centrifuge the food matrices to avoid clogging and did not monitor
any losses of toxin or complex in that process nor adherence to the
filters themselves. Perhaps magnetic beads would be more reliable
Figure 3. Deducing the sensitivity of selected anti-BoNT llama single domain antibodies. Lower limits of detection of the best antibody
pairs on cognate toxin and toxin complex for each serotype a) A, b) B, c) C, d) D, e) E, f) F, and g) G. To provide a non-specific background value for
each plot, the mMFI of the pairs employed on 1e+5 pg/well (i.e. 10x the top concentration used in this titration) of non-cognate serotypes are
provided as follows: A toxin, 2.3; A complex, 2.0; B toxin, 1.3; B complex, 2.0; C toxin, 8.0; C complex, 3.3; D toxin, 32.3; D complex, 4; E toxin, 2.8; E
complex; 3.5; F toxin, 4.5; F complex, 7.5; G toxin, 2.5; G complex, 2.0.
doi:10.1371/journal.pone.0008818.g003
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1e+4 pg per well of each of the toxin or toxin complexes in a) PBSTB, b) 2% reduced fat milk, c) orange juice d) carrot juice and e) cola.
doi:10.1371/journal.pone.0008818.g004
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[56]. Captor D (raised against a D/C mosaic) though relatively
specific with tracer D alone (table 1), here appeared to also capture
C complex (and C toxin in buffer) perhaps by virtue of tracer C
binding. While we have not matched the high sensitivities of and
breadth of foodstuffs tested by others [57] the methodology could
be improved using directed evolution of the sdAb genes and can
also be fully automated on the FDA approved Bioplex 2200. It
would certainly be exciting to test the current assay on ‘‘real world
samples’’ to give us an idea of whether our chosen clones are
indeed the best performers in harsh matrices and crude culture
filtrates.
Characterization of Anti-BoNT sdAb Subtype Specificity
The anti-A (A1) clones showed varying reactivity against A2
complex and we tabulated the A2 cross-reactivities for those
combinations already having the highest specificity for A1
(Table 2). While many (n=10) combinations were highly specific
for A1 (0–1% A2/A1 cross-reactivity), most (n=19) showed
marginal (1–10%) cross-reactivities, yet some (n=3) showed high
(80–100%) cross-reactivities. Our most sensitive combination of
A18 captor with A17 tracer was still capable of 32% cross-
reactivity. Based on extrapolation of data in figure 3a., we would
expect a lower limit of detection of approximately 300 pg (21
MLD50) of A2 complex and 100 pg of A2 toxin in a 50 mL sample
volume if a signal to noise ratio of 10 is used to define a positive.
We aim to further explore subtype specificity of anti-A clones and
other clones using synthetic gene assembly of BoNT domains since
rare subtypes can be fickle to obtain.
Inhibitory Effect of sdAb on BoNT Activity
We employed the neuro-2A assay to preliminarily explore any
inhibitory effects of sdAb on BoNT activity. The assay involves
combining toxin with antibody and incubating the mix over the
neuroblastoma monolayer for several days, after which, the
cleavage of the pertinent SNARE target is monitored. We
concentrated on our anti-A clones and show that six of the anti-
A clones (A1, A2, A8, A9, A16, A17) demonstrate reduced SNAP-
25 cleavage by virtue of a decrease in the amount of D-SNAP-25
relative to SNAP-25 itself (Figure 5). This assay and others like it
are complex and rather fickle since a relatively large amount of
toxin is required to elicit modest cleavage which can only be
monitored after cell collection, lysis and western blotting. That
these remarkable little antibodies 1/10
th the size of the toxins can
impact intoxication under these conditions certainly indicates
more decisive studies are needed. We hope to use more
streamlined assays that enable cleavage to be monitored in vivo
[58] for all of our clones and then deconvolute the sites of
inhibition. Since sdAb have been shown to be ideally suited for
inhibiting enzymes by intruding into their catalytic pockets [47],
exploring this potential with in vitro cleavage assays [59] will be
especially exciting!
Molecular Flexibility of the Anti-BoNT sdAb
We examined the refoldability of our best sdAb candidates using
circular dichroism (Figure S2, panels a-n) and found they varied in
their ability to regain a refolded state with C24, D22, F5, G3 and
G21 outperforming the rest (Table 3). Suspecting that molecular
heterogeneity may have been responsible for mediochre perfor-
mance in this assay we re-purified A17 and A18 on a larger scale
and subjected the proteins to more stringent chromatography
conditions such that by SDS-PAGE they were judged to be .98%
pure, yet saw the same CD signatures (data not shown). While we
chose the fastest cycling times and did not optimize buffer
conditions, nor explore chemical denaturation, it has been noted
previously that sdAb can vary widely in their molecular flexibility
and ability to refold [60]. Despite this, all but one of our
candidates (F9) appeared superior to the polyclonal conventional
IgG preparations (Figure S2, panels o-s).
Conclusions
In this work, our goal was not so much to compete with existing
diagnostics and therapeutics for BoNT but rather begin exploring
the capacity of a relatively novel type of antibody (sdAb or
nanobody) to probe the BoNT architectures for unique epitopes
and inhibitory activities. It appears that sdAb are capable of highly
specific BoNT recognition, perhaps by virtue of their smaller non-
antigen binding surface areas minimizing unwanted cross-
reactivities as opposed to larger multi-domain immunoglobulins.
Several sdAb were capable of acting as both captor and detector
for specific BoNT serotypes, indicating their potential as probes for
toxin and toxin complex higher order structures. A handful of anti-
A clones were also shown to inhibit the activity of BoNT A in a
tissue culture assay and it would be pertinent to determine if the
inhibition occurs via receptor blocking or at a later stage via uptake
[61].
We were impressed by the ability of a single llama to deliver a
broad range of ligands with good sensitivity and mostly exquisite
Table 2. Distribution of A2 cross-reactivities of the most
serotype A specific tracer captor pairs.
% cross-reactivity
on A2
Pairs with non-cognate
cross-reactivity ,=0.1%
Pairs with non-cognate
cross-reactivity ,=1%
0–1 2 8
1–10 5 14
10–20 4 4
20–40 5 4
40–60 2 2
60–80 0 2
80–100 0 3
doi:10.1371/journal.pone.0008818.t002
Figure 5. In vitro tissue culture assay to discover potential inhibitory activities of our sdAb clones. Neuro-2A assay demonstrating the
ability of some of the anti-A BoNT sdAb to inhibit the process of BoNT intoxication by reducing the intracellular cleavage of SNAP-25. + indicates toxin
without sdAb and – indicates no toxin and no sdAb.
doi:10.1371/journal.pone.0008818.g005
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(since they were so costly) of multiple immunogens that have been
shown to be far from native [62] and far from optimal in eliciting
the highest antibody titers [63,64]. Our low immune responses
and resulting mediochre limits of detection for serotype E and F
especially, would indicate that using newer more native toxoided
formulations [63,64], catalytically inactive mutants [65,66,67],
bead bound forms [56] or recombinant BoNT fragments
[14,18,68,69] may deliver a wider diversity of sdAb with higher
sensitivities. To our knowledge, these sdAb represent the first
recombinant antibodies specific for BoNT serotypes other than A,
B or E [70,71,72,73] and we hope these and future improved
derivatives will facilitate increased biosecurity. For example, many
new and promising detection systems can be super-sensitized with
an antibody capture step [74,75], and these may benefit from non-
inhibitory antibodies to less common BoNT serotypes.
It would be difficult to envision these current sdAb as
competitors with very promising immunotherapeutics derived
from fully human recombinant antibody cocktails [76] that are
aimed at clearing toxin appearing in serum prior to uptake by
susceptible neurons, since sdAb are likely to be both rapidly
cleared without modification [77] and then potentially immuno-
genic unless humanized. However, since such a countermeasure
must be given immediately after exposure, there is great interest in
novel approaches to inactivate/eliminate toxin once neuronal
uptake has occurred and botulism is fully apparent. Once inside
the neuron, toxin is refractory to conventional circulating
antibodies though may perhaps be targeted by anti-Lc sdAb
fusions as an Hc targeted intrabody [78]. It would also be tempting
to speculate that engineered anti-BoNT sdAb might also be one
day employed as efficacious oral anti-dotes with further rugged-
ization to counter the harsh gastric environment [79].
Materials and Methods
Materials
All BoNT toxoids, toxins, toxin complexes and anti-BoNT
rabbit polyclonal antibodies were from Metabiologics (Madison,
WI). The primary production strains used by Metabiologics were
A Hall, B Okra, C Brazil, D 5995, E Alaska, F Langeland, G 89,
and A2 complex was from FR1 honey isolate. Mouse lethal dose
50% (MLD50) per mg values were provided as follows: Toxins: A
2.7e+7, B 1.1e+8, C 2.4e+7, D 1.0e+8, E 6.0e+7, F 2.0e+7, G
1.4e+7; Complexes: A 3.5e+7, 9.5e+6, C 7.0e+6, 2.9e+7, E
3.0e+7, F 3.2e+6, G 3.9e+6, A2 7e+7. Both toxins and complexes
were provided at 1 mg/mL.
Biosafety
All protocols involving BoNT were approved by the SFBR
Biohazards and Safety Committee and carried out under the CDC
Select Agent Program following all applicable federal guidelines.
Llama Immunization
Institutional Animal Care and Use Committee (IACUC)
approval for this experiment was through the Triple J Farms
(Bellingham, WA) protocol application process. A single male
llama (Lama glama) named ‘‘Snoop’’ was immunized six times at 3
week intervals with a cocktail of toxoided botulinum neurotoxins.
Snoop is kept with ten other male llamas ranging in age from 4 to
20 years of age. All llamas are housed in an eight acre grass
paddock and have free access to a barn enclosure. All bleeds and
injections are done in the barn enclosure with the herd mates
present so as not to cause undue stress. The llamas used are
acclimatized to being handled and bled, so no anesthesia is
necessary. Triple J Farms IACUC committee inspects the facilities
at six month intervals and USDA inspections are done by their
veterinarians at least once a year. The first immunization was in
Freunds complete adjuvant and subsequent immunizations were
in Freunds incomplete adjuvant, all being one subcutaneous
injection. Each dose was 1 mL total, 500 mL of which was
adjuvant and 500 mL was phosphate buffered saline (PBS)
containing 10 mg of each toxin serotype as formalin cross-linked
toxoid. A 5 mL serum sample was taken one week prior to each
immunization for analysis of seroconversion, and a full bleed of
800 mL was taken 3 weeks after the final immunization.
Seroconversion Enzyme Linked Immunosorbant Assay
(ELISA)
100 mLo f1mg/mL of antigen in PBS was used to coat high
binding ELISA plate wells overnight at 4uC. Plates were washed 3
times with 175 mL PBS and blocked with 300 mL of PBS +2%
Carnation non fat dried milk (PBSM) for 1 h. Dilutions of serum
in PBSM were then applied for 1 h, the plates washed 3x with
175 mL PBS +0.1% Tween-20 (PBST) and 2x with PBS. 100 mLo f
a 1 in 10,000 dilution of goat anti-llama horseradish peroxidase
conjugate (Bethyl laboratories, Montgomery, TX) in PBSM was
applied for 1 h and the plates washed again. TMB-Ultra (Pierce,
Rockford, IL) was used for color development with sulfuric acid
stop solution and absorbances read on a microplate reader
(BioRad, Hercules, CA).
Isolating Antibody Genes
White blood cells were first separated from half of the whole
blood using UNI-SEPmaxi+ columns (Novamed, Jerusalem, Israel)
and then total RNA was extracted using Trizol (Invitrogen,
Carlsbad, CA). 10 mg of RNA was used in multiple 20 mL oligo-
dT primed reverse transcription reactions (Ambion, Austin, TX) to
generate cDNA. 2 mL aliquots were then used in 246100 mL
polymerase chain reaction (PCR) volumes with Hotstart YieldAce
(Stratagene, La Jolla, CA) using 95uC for 5 min, 256(95uC for 30 s,
50uC for30 s, 72uC for30 s)and 72uC for5 min. Thefront primers
were specific for the framework (FR) 1 region of llama variable
Table 3. Percent refoldedness of the most specific and
sensitive sdAb clones at each of the two cooling cycles.
sdAb cool 1 cool 2
A17 105.0 102.3
A18 52.2 32.2
B4 64.0 60.7
B2 70.4 59.3
C1 87.5 80.2
C24 93.8 93.2
D22 96.9 96.0
D16 100.9 97.3
E7 105.5 104.9
E4 89.4 86.7
F9 87.2 89.7
F5 98.9 99.3
G20 94.0 97.5
G3 87.7 85.2
doi:10.1371/journal.pone.0008818.t003
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MARCTGCAGSAGTCWGG-39 [80] and ‘‘PstN2’’=59-GATG-
TGCAGCTGCAGGCGTCTGGRGGAGG-39 [81]). The back
primer was specific for framework 4 and encoded a Not Is i t e
(‘‘GenNot’’ 59-AAAAAAGCGGCCGCTGAGGAGACGGTGA-
CCTG-39 based upon [82]). PCRproductswerephenolchloroform
extracted and ethanol precipitated, digested with Pst I and Not I and
ligated to similarly digested phage display vector pecan21
LgEBOZg which has an anti-Ebola NP sdAb providing the FR1
and FR4 scaffold (unpublished observations). Home-made electro-
competent XL-1 Blue were used in over 120 electroporations to
make the library of .1e+9 transformants. 24 clones were
miniprepped, mapped and sequenced to gauge the fidelity of the
library, which was then rescued with M13K07 and aliquots of
phage stored at 280uC long term.
Phage Selection and Screening for Anti-BoNT sdAb
100 mg amounts of toxins were individually biotinylated in
400 mL reactions using Sulfo-NHS-LC-Biotin (Pierce) and purified
on Zeba Desalt Spin Columns (Pierce). Biotinylation was
confirmed by comparing neutravidin capture efficiencies of
modified and unmodified toxins in ELISA employing Snoop
serum from the final bleed and anti-llama HRP as above (data not
shown).
In a 500 mL volume, 100 representations of each clone or 1e+11
phagemids were combined with 10 mL streptavidin coated M-280
magnetic beads (Dynal Biotech ASA, Oslo, Norway) on a rotisserie
to pre-absorb background binders for 1 h in PBS+2% bovine
serum albumin+0.05% Tween-20 (PBSBT). 100 nM of target
biotinylated toxin and 100 nM of each of the 6 unbiotinylated
non-target or decoy toxins were assembled in 500 mL PBST and
left to block for an hour. After magnetic capture of the beads, the
supernatant containing blocked phage was combined with the
toxin mix and rotissaried for 1 h. 10 mL of beads that had been
blocked in 1 mL of PBSBT were magnetically captured, the
supernatant removed, the phage/toxin mix added and rotated for
30 min to capture the biotinylated toxin and any specifically
bound phage. The beads were then captured and washed 5x with
900 mL of PBSBT over the course of about 10 min. Phage
remaining on the toxin were eluted with 500 mL 100 mM
triethylamine for 10 min and neutralized with 250 mL of 0.5 M
Tris-HCl pH 7.5. Half of this mix was used to infect exponential
phase XL1-Blue cells which were plated on selective medium and
rescued by super infection the next day according to standard
practices [83]. 2 to 4 rounds of panning were performed at 100,
20, 4 and 0.8 nM antigen concentration, with many clones
isolated after a single round. Polyclonal phage from round 2 was
analyzed on all 7 serotypes of toxins and toxin complexes to
determine if antigen specific clones were being enriched and a
minimum of 96 clones from each panning round was analyzed by
monoclonal ELISA on toxin as described above but employing
anti-M13HRP conjugate (GE Healthcare, Piscataway, NJ) as the
secondary antiserum. Positive clones having signals greater than
10x background were sequenced, amino acid sequences predicted
using BioEdit [84] and unique clones identified using Multalin
[85].
Isolating sdAb Proteins
Unique clones were mobilized from the phage display vector to
a soluble sdAb expression vector pecan45 LgEBOZg by Pst I/Not I
and resequenced before transfer to Rosetta (Novagen/EMD
Chemicals, Gibbstown, MD) for protein expression. Briefly,
saturated 40 mL overnight cultures grown in terrific broth (TB)
plus 2% glucose at 30uC were transferred to 400 mL of fresh TB
without glucose and shaken for 3 h at 25uC. Expression was
induced by addition of IPTG to 1 mM for 3 h at 25uC, the cells
pelleted (typical wet weights of 8–9 g) and osmotically shocked
[86] by resuspension in 14 mL ice-cold 0.75 M sucrose in 100 mM
Tris-HCl pH 7.5, addition of 1.4 mL of 1 mg/mL hen egg
lysozyme, followed by drop-wise addition of 28 mL of 1 mM
EDTA pH 7.5 and swirling on ice for 15 min. 2.0 mL of 0.5 M
MgCl2 was added, swirling continued for 15 min and cells
pelleted. The 45 mL supernatant (shockate) was mixed with
5 mL of 10xIMAC (immobilized metal affinity chromatography
buffer - 0.2 M Na2HPO4, 5 M NaCl, 0.2 M imidazole, 1%
Tween-20, pH 7.5), followed by 0.5 mL of High Peformance Ni
Separose (GE Healthcare) and the suspension gently mixed on ice
for 1 h. Resin was pelleted and washed twice with 2640 mL of
1xIMAC solution before elution with 2 mL of 0.45 M EDTA in
1xIMAC buffer. Proteins were concentrated in Amicon 10 kDa
ultrafiltration devices (Millipore, Billerica, MA) to 200 mL for
separation by gel filtration on a Superdex 200 HR 10/300 column
(GE Healthcare) operating in PBS. Proteins were quantified by
BCA assay (Pierce) and 10 mg analysed by SDS-PAGE and silver
staining for impurities.
Characterizing sdAb Proteins
To generate captor motifs, 10 mg of antibody was coupled to
Bioplex beads (BioRad) according to the manufacturer’s instruc-
tions to yield 150 mL of bead suspension. To generate tracer
motifs, 200 mg of protein was biotinylated with a 10 fold molar
excess of Sulfo-LC-NHS-biotin and purified as for the toxins to
yield 0.5 mg/uL solutions.
Cross-reactivity assays were performed in duplicate by combin-
ing 0.125 mL of each of the beadsets against a particular serotype
made in 50 mL of PBSBT with either 1e+5 pg of cognate toxin,
cognate toxin complex or 1e+5 pg of each of the other toxin or
toxin complex serotypes made in 50 mL. These mixes were
incubated with shaking in the dark for 30 min and then washed by
vacuum filtration twice with 175 mL PBSBT. 0.4 mL of a single
biotinylated tracer sdAb in 100 mL PBSBT (to give approx.
133 nM) was added to the wells, incubated with shaking for
30 min and washed as above. 100 mL of PBSTB containing
2.5 mL/mL PhycoLink strepatavidin-PE PJ31S (PROzyme, San
Leandro, CA) was added, wells shaken for 30 min, washed twice
and the beads resuspended in 130 mL of PBSBT. Plates were read
in a Bioplex (Biorad) with 100 events collected from each region to
yield a series of median fluorescence intensities (MFI). The captor
tracer pairs with mean MFI below 500 were discarded, and
remaining pairs tabulated for percentage cross-reactivities.
LOD assays were essentially performed as above except
threefold serial dilutions of toxin or toxin complex from
1e+4 pg/well in duplicate were employed in place of the fixed
1e+5 pg/well concentrations. Plots of duplicate MFI versus
concentration were used to evaluate the lower LOD by using a
value of 10 fold above background (set as non-cognate mMFI
given by 1e+5 pg/well).
Heptaplex assays were performed by combining all of the
selected pairs of beads and tracers, challenging them in duplicate
with 1e+4 pg/well of each of the toxins or toxin complexes diluted
in buffer, 2% reduced fat milk, orange juice (some pulp), carrot
juice or cola and plotting duplicate MFIs. The milk and orange
juice were microfuged prior to mixing with the beads.
Neuro-2A Intoxication Assay
Neuro-2A assays were performed by combining 10 mg of sdAb
with 2 mg of toxin in 0.5 mL of Eagle’s minimum essential
medium with Earle’s balanced salt solution, non essential amino
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penicillin and streptomycin, incubating for 1 h at 37uC and then
using the mix to replace supernatant on 90% confluent neuro-2A
cells (ATCC, CCL-131) in 24 well plates. After incubation for
48 hours at 37uCi n5 %C O 2 in a humidified incubator the
supernatant was aspirated, the cells were washed with serum free
media and then lysed with 75 mL of 20 mM HEPES, 50 mM
NaCl, 1% Triton X-100, pH 7.4 plus protease inhibitor cocktail
(Roche, Nutley, NJ). 30 mL was combined with 75 mL of Laemmli
sample buffer, boiled for 5 min and loaded on a 12% SDS-PAGE
gel. Following semi-dry transfer to Immobilon P the membranes
were blocked in 2% milk in PBS (MPBS) overnight. Probing was
with 1 in 1000 of mouse anti-SNAP, clones SP12 and 4H251
(Santa Cruz Biotechnology, Santa Cruz, CA) and 1 in 5000 of
mouse anti-actin clone C4 (Santa Cruz Biotechnology) followed by
1 in 10,000 of goat anti mouse IgG (H+L) HRP (Pierce, Rockford,
IL). Pico west (Pierce) and Fuji X-ray film were used to develop
and capture the images. The entire assay was repeated several
times to try and generate the clearest images, and the same subset
of clones appeared to show inhibitory effect each time.
Circular Dichroism of sdAb and Conventional
Immunoglobulins
Polyclonal antisera and sdAb were used at a concentration of
0.2 mg/mL in PBS. Data was collected in a 1 mm path length
cuvette at 216 nm with a JASCO J-815 CD spectropolarimeter
equipped with a temperature controlled Peltier cell holder. Data
points were collected every 0.5uC and the temperature was
increased from 20uCt o8 0o r9 0 uC and reversed at a rate of 10uC/
min. To calculate the percentage refolded, the data points at 80uC
were taken as 100% unfolded and values between 20 and 40uCo n
the curves were averaged and taken as the folded values. The
folded value of the cooling curve (1 or 2) was subtracted from
heating curve (1 or 2) and then divided by the 100% unfolded
value.
Supporting Information
Table S1 Chequerboard cross-reactivity assays of sdAb clones
on toxins and complexes to identify best captor/tracer combina-
tions. Duplicate median fluorescent intensities (MFI) and mean
MFI (mMFI) calculated for tracer/captor pairs employing 1e+5p g
of target versus non-target serotype to evaluate the percentage
cross-reactivity (% x-reactivity) S1) A toxin, S2) A complex, S3) B
toxin, S4) B complex, S5) C toxin, S6) C complex, S7) D toxin, S8)
D complex, S9) E toxin, S10) E complex, S11) F toxin, S12) F
complex, S13) G toxin, S14) G complex. The most specific
combinations with the largest expected dynamic range selected for
further study in limit of detection trials are highlighted in yellow.
Found at: doi:10.1371/journal.pone.0008818.s001 (0.61 MB
PDF)
Figure S1 Primary structures of anti-BoNT sdAb clones.
Predicted amino acid sequences of sdAb identified as positive by
monoclonal phage ELISA on each serotype of toxin: a) A toxin; b)
B toxin c) C toxin d) D toxin, e) E toxin, f) F toxin, g) G toxin.
Found at: doi:10.1371/journal.pone.0008818.s002 (0.13 MB
PDF)
Figure S2 Examining the refoldabilty of sdAb in contrast to
conventional immunoglobulins. Circular dichroism analysis of our
final captor tracer pairs of sdAb specific for each serotype versus
polyclonal immunoglobulins for those serotypes that were
available: a) A18, b) A17, c) B4, d) B2, e) C1, f) C24, g) D22, h)
D16, i) E7, j) E4, k) F9, l) F5, m) G20, n) G3 o) A Ig, p) B Ig, q) C
Ig, r) E Ig, s) F Ig. First heating=red, first cooling=dark blue,
second heating=green, second cooling=light blue.
Found at: doi:10.1371/journal.pone.0008818.s003 (0.15 MB
PDF)
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